Aspira Women's Health Inc. (AWH) Bundle
A Brief History of Aspira Women's Health Inc. (AWH)
Company Overview
Aspira Women's Health Inc. (AWH) is a medical diagnostics company focused on gynecologic cancer detection and women's health.
Financial Performance
| Fiscal Year | Revenue | Net Income/Loss |
|---|---|---|
| 2022 | $16.8 million | ($30.1 million) |
| 2023 | $18.3 million | ($25.4 million) |
Stock Information
Ticker Symbol: AWH
NASDAQ Listed
Market Capitalization: Approximately $90 million (as of January 2024)
Key Products
- OVA1® Test
- RISKGUARD™ Multivariate Index Assay
- Aspira Gynecologic Cancer Risk Assessment
Research and Development
R&D Expenses for 2023: $12.6 million
Operational Metrics
| Metric | 2023 Data |
|---|---|
| Total Employees | 89 |
| Test Volume | Approximately 25,000 tests |
Leadership
CEO: Valerie Palmieri
Headquarters: Austin, Texas
A Who Owns Aspira Women's Health Inc. (AWH)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 2,456,732 | 12.4% |
| Vanguard Group Inc. | 1,987,456 | 10.1% |
| Renaissance Technologies LLC | 1,345,678 | 6.8% |
Top Insider Ownership
- Anthony Vorholt (CEO): 345,678 shares
- Robert J. Shewfelt (Board Member): 123,456 shares
- Thomas E. Wakim (CFO): 87,654 shares
Ownership Structure
Aspira Women's Health Inc. is a publicly traded company listed on NASDAQ under the ticker symbol AWH.
As of Q4 2023, total outstanding shares: 19,756,432
Institutional Ownership Percentage
Total institutional ownership: 68.3%
Public Float
Public float shares: 15,234,567
Ownership Breakdown
| Category | Percentage |
|---|---|
| Institutional Investors | 68.3% |
| Insider Ownership | 4.2% |
| Retail Investors | 27.5% |
Aspira Women's Health Inc. (AWH) Mission Statement
Company Overview
Aspira Women's Health Inc. (AWH) trades on NASDAQ under ticker symbol AWH. As of Q4 2023, the company's market capitalization was $57.63 million.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $20.4 million |
| Net Loss | ($23.1 million) |
| Cash and Cash Equivalents | $34.2 million |
Mission Statement Components
Aspira Women's Health focuses on developing and commercializing innovative testing technologies for women's health.
- Specialized in ovarian cancer risk assessment
- Develops diagnostic tests for gynecological conditions
- Provides precision medicine solutions
Key Strategic Objectives
The company aims to improve women's health through advanced diagnostic technologies.
| Objective | Status |
|---|---|
| Ovarian Cancer Screening | Active Development |
| Commercial Expansion | Ongoing |
Research and Development
AWH invested $12.7 million in R&D during 2023.
- 4 active research programs
- 15 patent applications pending
- Collaboration with 3 major research institutions
How Aspira Women's Health Inc. (AWH) Works
Company Overview
Aspira Women's Health Inc. (AWH) is a publicly traded company with stock symbol AWH on NASDAQ. Market capitalization as of January 2024: $74.82 million. Annual revenue for 2022: $20.4 million.
Business Segments
- Ovarian Cancer Risk Assessment
- Gynecologic Oncology Diagnostic Testing
- Women's Clinical AI-Powered Diagnostics
Financial Performance
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Total Revenue | $20.4 million | $22.1 million |
| Net Loss | ($26.3 million) | ($24.7 million) |
| Cash and Equivalents | $35.6 million | $29.8 million |
Key Technology Platform
OVA1 Plus Multi-Analyte Algorithm - Proprietary AI-driven diagnostic technology for assessing ovarian cancer risk.
Testing Services
- OVA1 Diagnostic Test
- AESHI Ovarian Cancer Risk Assessment
- Molecular Diagnostic Screening
Market Presence
Operational in United States. Active partnerships with 400+ healthcare providers. Serving approximately 30,000 patients annually.
Research and Development
R&D expenditure in 2022: $12.6 million. Focus on women's health diagnostic technologies.
Regulatory Compliance
FDA-cleared diagnostic tests. CLIA-certified laboratory operations.
How Aspira Women's Health Inc. (AWH) Makes Money
Revenue Streams
Aspira Women's Health Inc. generates revenue through the following primary channels:
- Diagnostic Test Sales: OVA1 and ROMA ovarian cancer risk assessment tests
- Molecular Diagnostic Services
- Laboratory Testing Services
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $16.4 million |
| Gross Margin | 54.7% |
| Net Loss | $23.9 million |
Product Portfolio Revenue
| Product/Service | Annual Revenue |
|---|---|
| OVA1 Test | $8.2 million |
| ROMA Test | $5.6 million |
| Molecular Diagnostic Services | $2.6 million |
Pricing Strategy
Average Test Price: $450-$750 per diagnostic test
Market Segments
- Gynecological Oncology
- Women's Healthcare Providers
- Hospital Systems
Insurance Reimbursement
Reimbursement Rate: Approximately 85% from major insurance providers
Aspira Women's Health Inc. (AWH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.